Definiens Launches Clinical Development Offering to Provide Services from Discovery to Commercialization to Maximize the Success of Drug Programs

MUNICH–(BUSINESS WIRE)– Definiens,
the pioneer in Tissue Phenomics solutions for diagnostic development and
commercialization, today announced the release of its Clinical
Development Offering, making the company the premier provider of
comprehensive tissue-based services from discovery to commercialization.
The new service enables pharmaceutical companies to improve patient
outcomes and reduce pipeline risk, ultimately moving therapies to market
more quickly and improving the success of drug programs.

Leveraging Tissue Phenomics, Definiens provides robust and precise
quantitative IHC, ISH, and IF assays to identify tissue features in
context that can be easily combined with other data types to mine for
clinically relevant patterns.

“The focus of our new Definiens clinical development offering is to
support our partners in maximizing their pipeline, to accurately
identify patient populations and therefore deliver the right therapy,”
said Thomas Heydler, CEO, Definiens. “We are now providing image
analysis, data mining and assay development, combined with deep
scientific, regulatory and pathology support. It’s truly an end-to-end
offering for biopharma,” he adds.

The Clinical Development Offering provides a number of services:

Clinical Trial Services

• Drive Pipeline Decisions: Gain biological insights from custom
  tissue-based assays & quantitative image analysis solutions to drive
  pipeline decisions in your clinical trials.

Signature Discovery Services

• Discover the Best Signatures: Utilize our unparalleled data
  mining on your tissue samples to find novel signatures and assess the
  potential of a biomarker to identify patient populations.

Companion Diagnostics Services

• Deliver Precise CDx to the Market: With precise quantitative
  biomarker readouts, best-in-class, co-developed assays ensure fast
  movement from prototype to regulatory filing.

To learn more about Definiens’ Clinical Development Offering, please contact
us. For more information about Definiens, visit www.definiens.com.

About Definiens

Definiens is the pioneering provider of Tissue Phenomics® solutions for
biomarker and companion diagnostics development and commercialization.
Definiens’ technology empowers smarter tissue-based diagnostics by
leveraging quantitative tissue readouts and other big data sources. By
enabling the development of powerful and precise assays for patient
stratification and clinical trial enrollment, Definiens aims to
dramatically improve patient outcomes. Definiens’ Tissue Phenomics
approach was awarded the 2013 Frost and Sullivan Company of the Year
Award for Global Tissue Diagnostics and Pathology Imaging. For more
information, please visit: www.definiens.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160802005055/en/